Russell Barton
Direttore operativo presso ACUMEN PHARMACEUTICALS, INC.
Patrimonio netto: 309 006 $ in data 30/04/2024
Posizioni attive di Russell Barton
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ACUMEN PHARMACEUTICALS, INC. | Direttore operativo | 01/04/2019 | - |
AgeneBio, Inc.
 AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Direttore Tecnico/Scientifico/R&S | 01/10/2019 | - |
| Pharma Sagacity Consulting LLC | Presidente | 01/01/2018 | - |
Storia della carriera di Russell Barton
Precedenti posizioni note di Russell Barton
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ELI LILLY AND COMPANY | Direttore operativo | - | - |
Formazione di Russell Barton
| Illinois State University | Undergraduate Degree |
| Purdue University | Graduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| Chief Operating Officer | 2 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Settori
| Health Technology | 4 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| ACUMEN PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 2 |
|---|---|
AgeneBio, Inc.
AgeneBio, Inc. BiotechnologyHealth Technology AgeneBio, Inc. develops an innovative therapeutics for unserved patients afflicted with neurological and psychiatric diseases to preserve and restore brain function. It research focused on cognitive neuroscience and the neurobiology of the aging brain with most advanced clinical program targets amnestic mild cognitive impairment (aMCI), the symptomatic, pre-dementia stage of Alzheimer’s. The company was founded by Michela Gallagher in 2008 and is headquartered in Baltimore, MD. | Health Technology |
| Pharma Sagacity Consulting LLC |
- Borsa valori
- Insiders
- Russell Barton
- Esperienza